Pharmacyclics Reports Second Quarter 2013 Results

barbara.lempert SUNNYVALE, Calif., July 31, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today reported financial results and recent developments ...

Actelion enters into an agreement to acquire privately-held Ceptaris Therapeutics

barbara.lempert VALCHLOR(TM) gel under FDA Review for Early-Stage Mycosis Fungoides-Type CTCL ALLSCHWIL/BASEL, SWITZERLAND and MALVERN, PA – 31 July 2013 – Actelion US ...

Nearly 450 Innovative Medicines in Development for Neurological Disorders

barbara.lempert WASHINGTON, D.C. (July 31, 2013) – America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, ...

McKesson Shareholders Vote In Favor Of A Clawback Policy

esilverman Shareholders for McKesson, one of the largest pharmaceutical wholesalers in the US, voted in favor of instituting a clawback policy that was proposed by two institutional ...

Naurex Announces Issuance of New Patent for Novel Antidepressant Glyx-13

barbara.lempert —Extends Patent Life to 2030 for Novel Agent that Demonstrated Rapid Onset, Robust Efficacy and Good Safety in a Phase II Trial—   EVANSTON, IL – July 30, ...

Tweets of the day, 7/31/2013

chris.truelove by Christiane Truelove (chris.truelove@ubm.com) It’s another summer fun day of news in Pharma-land. Over at Pharmalot, Ed Silverman shows how CME funding has gone ...

Report: Alexion taps financial advisers for potential Roche deal

Tracy Staton Bloomberg has revived speculation about a potential acquisition of Alexion, reporting that Alexion has brought in Goldman Sachs to advise the company after Roche made an ...

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin

barbara.lempert Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108) All amounts are in U.S. dollars (unless ...

Actelion snags lymphoma drug in $250M buyout deal for Ceptaris

John Carroll Switzerland's Actelion has struck a deal to buy Malvern, PA-based Ceptaris Therapeutics for $ 250 million–provided the FDA comes through with an approval of ...

AstraZeneca reportedly eyeing deal for Korean biosim maker Celltrion

Carly Helfand Celltrion confirmed Wednesday that its largest shareholder is in discussions with financial adviser JPMorgan but stressed in a statement that "no definite structure, ...

Forest, Amerigen in Generic Deal

barbara.lempert Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of ...

FDA clears Merck’s Januvia, sister meds of new pancreatitis worries

Tracy Staton The group of drugs, known as incretin mimetics, was cleared last week by FDA's counterparts in Europe. FiercePharma News
Page 1 of 6112345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS